ClinicalTrials.gg
CompletedNCT00574548Updated Jul 22, 2011Results posted

Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

A Phase 3 interventional study of 13 valent Pneumococcal Conjugate Vaccine and 13 valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccines, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 6 sites in United States. Open to participants aged 60 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-07-22.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
60 Years to 64 Years
Sex
All
01

Study summary

The objective of this study is to compare the safety, tolerability and immunologic response to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that have never received a previous dose of 23vPS.

02

Conditions studied

  • Pneumococcal Vaccines

Keywords

  • Vaccines, Pneumococcal Conjugate Vaccine
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female, aged 60 to 64 years.
  • Healthy.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with any licensed or experimental pneumococcal vaccine.
  • History of severe adverse reaction associated with a vaccine.
  • Immunodeficiency.
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
720 participants (actual)

Study arms

  • Experimental
    Group 1.1

    Group 1.1 = 13vPnC then 13vPnC

    Biological: 13 valent Pneumococcal Conjugate Vaccine

  • Experimental
    Group 1.2

    Group 1.2 = 13vPnC then 23vPS

    Biological: 13 valent Pneumococcal Conjugate Vaccine · Biological: 23-valent Pneumococcal Polysaccharide Vaccine

  • Experimental
    Group 2

    Group 2 = 23vPS then 13vPnC

    Biological: 13 valent Pneumococcal Conjugate Vaccine · Biological: 23-valent Pneumococcal Polysaccharide Vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 23vPS (Year 0)

    Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

  2. Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS Versus 23vPS / 13vPnC (Year 1)

    Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

Secondary outcomes

  1. Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Year 1) Versus 13vPnC (Year 0)

    Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for the pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). The 6A pneumococcal serotype is specific to 13vPnC. Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

  2. Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 13vPnC (Year 0)

    Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

Other outcomes

  1. Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 23vPS / 13vPnC (Year 1) Versus 13vPnC (Year 0)

    Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

  2. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 1 (Year 0) 13vPnC and 23vPS

    Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

    Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

  3. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1)

    Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

    Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

  4. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1)

    Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

    Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

  5. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 23vPS (Year 0) and 13vPnC / 23vPS (Year 1)

    Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]); Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

    Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

  6. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 2 (Year 1) 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC

    Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

    Time frame: 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

  7. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 1 (Year 0) 13vPnC and 23vPS

    Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.

    Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1])

  8. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1)

    Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.

    Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

  9. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1)

    Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.

    Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

  10. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 23vPS (Year 0) and 13vPnC / 23vPS (Year 1)

    Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.

    Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

  11. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 2 (Year 1) 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC

    Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.

    Time frame: 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)

07

Results

Posted May 9, 2011

Participant flow

Participant flow — Overall Study
Milestone13vPnC - Group 1.1 or 1.223vPS - Group 2
Started482238
Received vaccination 1 (vax 1)478237
Completed vax 1 (6 month contact)468234
Withdrawn after vax 1 (6 month contact)73
Withdrawn before vax 24111
Received vax 2427223
Completed vax 2 (6 month contact)421222
Completed421222
Not completed6116

Outcome measures

PrimaryPneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 23vPS (Year 0)

Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Geometric mean · geometric mean titer
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 23vPS (Year 0)
geometric mean titer13vPnC / 23vPS23vPS
Common Serotype 1148 (123.7 to 176.5)148 (117.9 to 185.9)
Common Serotype 3125 (108.6 to 143.4)80 (67.5 to 95.7)
Common Serotype 41385 (1171.2 to 1638.7)1357 (1023.0 to 1799.0)
Common Serotype 5199 (161.4 to 246.2)140 (107.0 to 183.5)
Common Serotype 6B1215 (965.4 to 1528.3)706 (522.1 to 954.0)
Common Serotype 7F537 (422.4 to 682.6)331 (233.5 to 469.1)
Common Serotype 9V373 (268.4 to 517.6)288 (198.0 to 419.1)
Common Serotype 14622 (485.7 to 796.4)734 (543.6 to 990.1)
Common Serotype 18C1062 (863.2 to 1307.6)789 (586.2 to 1062.2)
Common Serotype 19A467 (403.5 to 541.0)376 (302.8 to 465.7)
Common Serotype 19F774 (642.0 to 933.6)509 (385.5 to 672.9)
Common Serotype 23F198 (151.2 to 259.4)70 (49.9 to 97.3)
Statistical analysis
  • 13vPnC / 23vPS vs 23vPS · Ratio of geometric mean titer: 1.0 · 95% CI 0.75 to 1.33CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS\]).
  • 13vPnC / 23vPS vs 23vPS · Ratio of geometric mean titer: 1.6 · 95% CI 1.24 to 1.94CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS\]).
  • 13vPnC / 23vPS vs 23vPS · Ratio of geometric mean titer: 1.0 · 95% CI 0.74 to 1.41CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS\]).
  • 13vPnC / 23vPS vs 23vPS · Ratio of geometric mean titer: 1.4 · 95% CI 1.01 to 2.00CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS\]).
  • 13vPnC / 23vPS vs 23vPS · Ratio of geometric mean titer: 1.7 · 95% CI 1.18 to 2.51CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS\]).
  • 13vPnC / 23vPS vs 23vPS · Ratio of geometric mean titer: 1.6 · 95% CI 1.07 to 2.47CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS\]).
  • 13vPnC / 23vPS vs 23vPS · Ratio of geometric mean titer: 1.3 · 95% CI 0.79 to 2.12CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS\]).
  • 13vPnC / 23vPS vs 23vPS · Ratio of geometric mean titer: 0.8 · 95% CI 0.58 to 1.25CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS\]).
  • 13vPnC / 23vPS vs 23vPS · Ratio of geometric mean titer: 1.3 · 95% CI 0.94 to 1.93CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS\]).
  • 13vPnC / 23vPS vs 23vPS · Ratio of geometric mean titer: 1.2 · 95% CI 0.96 to 1.61CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS\]).
  • 13vPnC / 23vPS vs 23vPS · Ratio of geometric mean titer: 1.5 · 95% CI 1.09 to 2.12CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS\]).
  • 13vPnC / 23vPS vs 23vPS · Ratio of geometric mean titer: 2.8 · 95% CI 1.86 to 4.35CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS\]).
PrimaryPneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS Versus 23vPS / 13vPnC (Year 1)

Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Geometric mean · geometric mean titer
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS Versus 23vPS / 13vPnC (Year 1)
geometric mean titer13vPnC / 23vPS23vPS / 13vPnC
Common Serotype 1148 (123.7 to 176.5)77 (60.7 to 98.1)
Common Serotype 3125 (108.6 to 143.4)50 (40.9 to 61.7)
Common Serotype 41385 (1171.2 to 1638.7)935 (739.9 to 1182.4)
Common Serotype 5199 (161.4 to 246.2)85 (64.2 to 112.0)
Common Serotype 6B1215 (965.4 to 1528.3)710 (529.1 to 953.2)
Common Serotype 7F537 (422.4 to 682.6)126 (85.6 to 184.6)
Common Serotype 9V373 (268.4 to 517.6)114 (76.5 to 169.3)
Common Serotype 14622 (485.7 to 796.4)435 (323.0 to 585.7)
Common Serotype 18C1062 (863.2 to 1307.6)564 (418.2 to 761.7)
Common Serotype 19A467 (403.5 to 541.0)289 (235.7 to 353.9)
Common Serotype 19F774 (642.0 to 933.6)286 (217.3 to 376.7)
Common Serotype 23F198 (151.2 to 259.4)124 (88.2 to 173.0)
Statistical analysis
  • 13vPnC / 23vPS vs 23vPS / 13vPnC · Ratio of geometric mean titer: 1.9 · 95% CI 1.43 to 2.57CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS / 13vPnC\]).
  • 13vPnC / 23vPS vs 23vPS / 13vPnC · Ratio of geometric mean titer: 2.5 · 95% CI 1.95 to 3.16CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS / 13vPnC\]).
  • 13vPnC / 23vPS vs 23vPS / 13vPnC · Ratio of geometric mean titer: 1.5 · 95% CI 1.12 to 1.96CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS / 13vPnC\]).
  • 13vPnC / 23vPS vs 23vPS / 13vPnC · Ratio of geometric mean titer: 2.4 · 95% CI 1.67 to 3.31CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS / 13vPnC\]).
  • 13vPnC / 23vPS vs 23vPS / 13vPnC · Ratio of geometric mean titer: 1.7 · 95% CI 1.19 to 2.47CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS / 13vPnC\]).
  • 13vPnC / 23vPS vs 23vPS / 13vPnC · Ratio of geometric mean titer: 4.3 · 95% CI 2.76 to 6.61CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS / 13vPnC\]).
  • 13vPnC / 23vPS vs 23vPS / 13vPnC · Ratio of geometric mean titer: 3.3 · 95% CI 1.97 to 5.45CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS / 13vPnC\]).
  • 13vPnC / 23vPS vs 23vPS / 13vPnC · Ratio of geometric mean titer: 1.4 · 95% CI 0.98 to 2.10CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS / 13vPnC\]).
  • 13vPnC / 23vPS vs 23vPS / 13vPnC · Ratio of geometric mean titer: 1.9 · 95% CI 1.32 to 2.69CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS / 13vPnC\]).
  • 13vPnC / 23vPS vs 23vPS / 13vPnC · Ratio of geometric mean titer: 1.6 · 95% CI 1.27 to 2.07CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS / 13vPnC\]).
  • 13vPnC / 23vPS vs 23vPS / 13vPnC · Ratio of geometric mean titer: 2.7 · 95% CI 1.96 to 3.74CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS / 13vPnC\]).
  • 13vPnC / 23vPS vs 23vPS / 13vPnC · Ratio of geometric mean titer: 1.6 · 95% CI 1.05 to 2.45CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC / 23vPS\] - \[23vPS / 13vPnC\]).
SecondaryPneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Year 1) Versus 13vPnC (Year 0)

Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for the pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). The 6A pneumococcal serotype is specific to 13vPnC. Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Geometric mean · geometric mean titer
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Year 1) Versus 13vPnC (Year 0)
geometric mean titer13vPnC Vaccination 1 (Year 0)13vPnC / 13vPnC Vaccination 2 (Year 1)
Common Serotype 1215 (163.9 to 282.4)142 (112.2 to 180.4)
Common Serotype 373 (57.2 to 94.1)89 (75.2 to 105.4)
Common Serotype 42255 (1625.2 to 3128.6)1214 (931.8 to 1582.1)
Common Serotype 5170 (112.1 to 258.6)98 (69.6 to 136.6)
Additional Serotype 6A2682 (1969.5 to 3652.1)2281 (1747.1 to 2978.5)
Common Serotype 6B2112 (1508.0 to 2958.2)1882 (1429.7 to 2477.9)
Common Serotype 7F930 (602.1 to 1437.1)323 (215.8 to 482.8)
Common Serotype 9V919 (619.1 to 1364.0)335 (214.6 to 522.6)
Common Serotype 14492 (312.7 to 774.5)384 (262.4 to 561.2)
Common Serotype 18C1440 (1015.3 to 2043.5)986 (730.8 to 1330.2)
Common Serotype 19A583 (426.6 to 796.8)385 (308.2 to 481.6)
Common Serotype 19F566 (385.7 to 829.2)502 (381.3 to 662.1)
Common Serotype 23F291 (187.7 to 452.2)456 (322.4 to 644.7)
Statistical analysis
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 13vPnC Vaccination 2 (Year 1) · Geometric mean fold rise: 0.7 · 95% CI 0.54 to 0.82CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 13vPnC Vaccination 2 (Year 1) · Geometric mean fold rise: 1.2 · 95% CI 0.99 to 1.49CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 13vPnC Vaccination 2 (Year 1) · Geometric mean fold rise: 0.5 · 95% CI 0.43 to 0.68CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 13vPnC Vaccination 2 (Year 1) · Geometric mean fold rise: 0.6 · 95% CI 0.43 to 0.77CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 13vPnC Vaccination 2 (Year 1) · Geometric mean fold rise: 0.9 · 95% CI 0.67 to 1.08CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 13vPnC Vaccination 2 (Year 1) · Geometric mean fold rise: 0.9 · 95% CI 0.71 to 1.12CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 13vPnC Vaccination 2 (Year 1) · Geometric mean fold rise: 0.3 · 95% CI 0.24 to 0.49CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 13vPnC Vaccination 2 (Year 1) · Geometric mean fold rise: 0.4 · 95% CI 0.26 to 0.51CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 13vPnC Vaccination 2 (Year 1) · Geometric mean fold rise: 0.8 · 95% CI 0.60 to 1.02CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 13vPnC Vaccination 2 (Year 1) · Geometric mean fold rise: 0.7 · 95% CI 0.54 to 0.87CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 13vPnC Vaccination 2 (Year 1) · Geometric mean fold rise: 0.7 · 95% CI 0.53 to 0.82CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 13vPnC Vaccination 2 (Year 1) · Geometric mean fold rise: 0.9 · 95% CI 0.69 to 1.15CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 13vPnC Vaccination 2 (Year 1) · Geometric mean fold rise: 1.6 · 95% CI 1.15 to 2.13CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
SecondaryPneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 13vPnC (Year 0)

Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Geometric mean · geometric mean titer
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 13vPnC (Year 0)
geometric mean titer13vPnC Vaccination 1 (Year 0)13vPnC / 23vPS Vaccination 2 (Year 1)
Common Serotype 1220 (178.9 to 269.3)140 (117.4 to 168.1)
Common Serotype 374 (61.3 to 88.7)129 (112.4 to 147.5)
Common Serotype 42517 (2091.7 to 3029.2)1430 (1214.7 to 1683.9)
Common Serotype 5227 (170.9 to 300.5)188 (151.1 to 234.8)
Common Serotype 6B2012 (1571.9 to 2574.1)1351 (1087.6 to 1677.0)
Common Serotype 7F1252 (971.1 to 1614.4)533 (419.2 to 678.2)
Common Serotype 9V758 (563.8 to 1018.9)406 (292.3 to 564.6)
Common Serotype 14664 (485.1 to 908.5)616 (473.3 to 802.2)
Common Serotype 18C1532 (1183.7 to 1982.7)1074 (871.7 to 1322.2)
Common Serotype 19A696 (581.1 to 833.6)457 (389.5 to 536.3)
Common Serotype 19F696 (546.3 to 887.7)773 (636.6 to 937.6)
Common Serotype 23F358 (265.5 to 481.7)216 (165.0 to 282.7)
Statistical analysis
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 23vPS Vaccination 2 (Year 1) · Geometric mean fold rise: 0.6 · 95% CI 0.55 to 0.75CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 23vPS Vaccination 2 (Year 1) · Geometric mean fold rise: 1.7 · 95% CI 1.52 to 2.01CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 23vPS Vaccination 2 (Year 1) · Geometric mean fold rise: 0.6 · 95% CI 0.49 to 0.66CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 23vPS Vaccination 2 (Year 1) · Geometric mean fold rise: 0.8 · 95% CI 0.67 to 1.03CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 23vPS Vaccination 2 (Year 1) · Geometric mean fold rise: 0.7 · 95% CI 0.57 to 0.79CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 23vPS Vaccination 2 (Year 1) · Geometric mean fold rise: 0.4 · 95% CI 0.35 to 0.52CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 23vPS Vaccination 2 (Year 1) · Geometric mean fold rise: 0.5 · 95% CI 0.41 to 0.69CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 23vPS Vaccination 2 (Year 1) · Geometric mean fold rise: 0.9 · 95% CI 0.75 to 1.15CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 23vPS Vaccination 2 (Year 1) · Geometric mean fold rise: 0.7 · 95% CI 0.58 to 0.85CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 23vPS Vaccination 2 (Year 1) · Geometric mean fold rise: 0.7 · 95% CI 0.58 to 0.74CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 23vPS Vaccination 2 (Year 1) · Geometric mean fold rise: 1.1 · 95% CI 0.89 to 1.39CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 13vPnC Vaccination 1 (Year 0) vs 13vPnC / 23vPS Vaccination 2 (Year 1) · Geometric mean fold rise: 0.6 · 95% CI 0.50 to 0.73CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.
Other pre-specifiedPneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 23vPS / 13vPnC (Year 1) Versus 13vPnC (Year 0)

Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Geometric mean · geometric mean titer
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 23vPS / 13vPnC (Year 1) Versus 13vPnC (Year 0)
geometric mean titer13vPnC23vPS / 13vPnC
Common Serotype 1207 (177.7 to 240.9)77 (60.7 to 98.1)
Common Serotype 375 (66.0 to 85.3)50 (40.9 to 61.7)
Common Serotype 42536 (2192.3 to 2933.0)935 (739.9 to 1182.4)
Common Serotype 5215 (175.9 to 261.7)85 (64.2 to 112.0)
Common Serotype 6B1948 (1614.0 to 2351.7)710 (529.1 to 953.2)
Common Serotype 7F1063 (868.6 to 1302.2)126 (85.6 to 184.6)
Common Serotype 9V767 (620.0 to 949.3)114 (76.5 to 169.3)
Common Serotype 14650 (524.9 to 805.8)435 (323.0 to 585.7)
Common Serotype 18C1576 (1321.3 to 1880.9)564 (418.2 to 761.7)
Common Serotype 19A709 (618.9 to 811.2)289 (235.7 to 353.9)
Common Serotype 19F711 (595.9 to 848.9)286 (217.3 to 376.7)
Common Serotype 23F354 (283.8 to 440.7)124 (88.2 to 173.0)
Statistical analysis
  • 13vPnC vs 23vPS / 13vPnC · Ratio of geometric mean titer: 2.7 · 95% CI 2.03 to 3.55CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC\] - \[23vPS / 13vPnC\]).
  • 13vPnC vs 23vPS / 13vPnC · Ratio of geometric mean titer: 1.5 · 95% CI 1.18 to 1.89CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC\] - \[23vPS / 13vPnC\]).
  • 13vPnC vs 23vPS / 13vPnC · Ratio of geometric mean titer: 2.7 · 95% CI 2.07 to 3.55CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC\] - \[23vPS / 13vPnC\]).
  • 13vPnC vs 23vPS / 13vPnC · Ratio of geometric mean titer: 2.5 · 95% CI 1.77 to 3.61CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC\] - \[23vPS / 13vPnC\]).
  • 13vPnC vs 23vPS / 13vPnC · Ratio of geometric mean titer: 2.7 · 95% CI 1.94 to 3.88CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC\] - \[23vPS / 13vPnC\]).
  • 13vPnC vs 23vPS / 13vPnC · Ratio of geometric mean titer: 8.5 · 95% CI 5.68 to 12.60CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC\] - \[23vPS / 13vPnC\]).
  • 13vPnC vs 23vPS / 13vPnC · Ratio of geometric mean titer: 6.7 · 95% CI 4.45 to 10.22CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC\] - \[23vPS / 13vPnC\]).
  • 13vPnC vs 23vPS / 13vPnC · Ratio of geometric mean titer: 1.5 · 95% CI 1.02 to 2.18CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC\] - \[23vPS / 13vPnC\]).
  • 13vPnC vs 23vPS / 13vPnC · Ratio of geometric mean titer: 2.8 · 95% CI 2.01 to 3.89CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC\] - \[23vPS / 13vPnC\]).
  • 13vPnC vs 23vPS / 13vPnC · Ratio of geometric mean titer: 2.5 · 95% CI 1.92 to 3.13CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC\] - \[23vPS / 13vPnC\]).
  • 13vPnC vs 23vPS / 13vPnC · Ratio of geometric mean titer: 2.5 · 95% CI 1.80 to 3.44CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC\] - \[23vPS / 13vPnC\]).
  • 13vPnC vs 23vPS / 13vPnC · Ratio of geometric mean titer: 2.9 · 95% CI 1.92 to 4.28CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (\[13vPnC\] - \[23vPS / 13vPnC\]).
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 1 (Year 0) 13vPnC and 23vPS

Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

Time frame:
14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 1 (Year 0) 13vPnC and 23vPS
percentage of participants13vPnC23vPS
Redness: Any (n=270, 134)12.211.2
Redness: Mild (n=266, 134)8.39.7
Redness: Moderate (n=264, 128)6.43.9
Redness: Severe (n=259, 127)1.20.8
Swelling: Any (n=270, 135)10.010.4
Swelling: Mild (n=268, 132)8.26.1
Swelling: Moderate (n=263, 132)3.87.6
Swelling: Severe (n=258, 127)0.00.0
Pain: Any (n=370, 175)69.258.3
Pain: Mild (n=360, 170)66.152.9
Pain: Moderate (n=284, 143)20.121.7
Pain: Severe (n=261, 127)2.30.8
Limitation of arm movement: Any (n=289, 142)23.528.2
Limitation of arm movement: Mild (n=286, 142)22.726.1
Limitation of arm movement: Moderate (n=260, 127)1.23.1
Limitation of arm movement: Severe (n=261, 128)1.12.3
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1)

Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

Time frame:
14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1)
percentage of participants13vPnC13vPnC / 13vPnC
Redness: Any (n=61, 61)14.811.5
Redness: Mild (n=57, 57)7.08.8
Redness: Moderate (n=58, 58)8.63.4
Redness: Severe (n=57, 57)0.03.5
Swelling: Any (n=60, 60)10.011.7
Swelling: Mild (n=59, 59)6.88.5
Swelling: Moderate (n=55, 55)1.83.6
Swelling: Severe (n=56, 56)0.01.8
Pain: Any (n=108, 108)76.975.9
Pain: Mild (n=101, 101)72.372.3
Pain: Moderate (n=61, 61)21.326.2
Pain: Severe (n=57, 57)0.03.5
Limitation of arm movement: Any (n=65, 65)26.224.6
Limitation of arm movement: Mild (n=65, 65)26.224.6
Limitation of arm movement: Moderate (n=56, 56)1.80.0
Limitation of arm movement: Severe (n=56, 56)0.01.8
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1)

Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

Time frame:
14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1)
percentage of participants13vPnC23vPS / 13vPnC
Redness: Any (n=270, 115)12.24.3
Redness: Mild (n=266, 115)8.34.3
Redness: Moderate (n=264, 115)6.40.9
Redness: Severe (n=259, 115)1.20.0
Swelling: Any (n=270, 119)10.05.0
Swelling: Mild (n=268, 119)8.25.0
Swelling: Moderate (n=263, 116)3.80.9
Swelling: Severe (n=258, 115)0.00.0
Pain: Any (n=370, 169)69.269.8
Pain: Mild (n=360, 166)66.168.1
Pain: Moderate (n=284, 129)20.117.8
Pain: Severe (n=261, 116)2.30.9
Limitation of arm movement: Any (n=289, 130)23.518.5
Limitation of arm movement: Mild (n=286, 130)22.716.9
Limitation of arm movement: Moderate (n=260, 115)1.20.0
Limitation of arm movement: Severe (n=261, 115)1.11.7
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 23vPS (Year 0) and 13vPnC / 23vPS (Year 1)

Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]); Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

Time frame:
14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 23vPS (Year 0) and 13vPnC / 23vPS (Year 1)
percentage of participants23vPS13vPnC / 23vPS
Redness: Any (n=134, 151)11.227.8
Redness: Mild (n=134, 144)9.719.4
Redness: Moderate (n=128, 138)3.912.3
Redness: Severe (n=127, 131)0.86.9
Swelling: Any (n=135, 155)10.425.8
Swelling: Mild (n=132, 149)6.120.1
Swelling: Moderate (n=132, 138)7.612.3
Swelling: Severe (n=127, 132)0.06.1
Pain: Any (n=175, 231)58.385.7
Pain: Mild (n=170, 205)52.978.5
Pain: Moderate (n=143, 176)21.749.4
Pain: Severe (n=127, 140)0.812.9
Limitation of arm movement: Any (n=142, 178)28.253.4
Limitation of arm movement: Mild (n=142, 171)26.147.4
Limitation of arm movement: Moderate (n=127, 134)3.110.4
Limitation of arm movement: Severe (n=128, 135)2.38.1
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 2 (Year 1) 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC

Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

Time frame:
14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 2 (Year 1) 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC
percentage of participants13vPnC / 13vPnC13vPnC / 23vPS23vPS / 13vPnC
Redness: Any (n=86, 151, 115)12.827.84.3
Redness: Mild (n=83, 144, 115)7.219.44.3
Redness: Moderate (n=83, 138, 115)7.212.30.9
Redness: Severe (n=83, 131, 115)2.46.90.0
Swelling: Any (n=86, 155, 119)14.025.85.0
Swelling: Mild (n=85, 149, 119)10.620.15.0
Swelling: Moderate (n=82, 138, 116)6.112.30.9
Swelling: Severe (n=82, 132, 115)1.26.10.0
Pain: Any (n=129, 231, 169)75.285.769.8
Pain: Mild (n=123, 205, 166)72.478.568.1
Pain: Moderate (n=91, 176, 129)24.249.417.8
Pain: Severe (n=83, 140, 116)2.412.90.9
Limitation of arm movement: Any (n=93, 178, 130)28.053.418.5
Limitation of arm movement: Mild (n=92, 171, 130)27.247.416.9
Limitation of arm movement: Moderate(n=83,134,115)3.610.40.0
Limitation of arm movement: Severe (n=82, 135,115)1.28.11.7
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 1 (Year 0) 13vPnC and 23vPS

Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.

Time frame:
14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1])
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 1 (Year 0) 13vPnC and 23vPS
percentage of participants13vPnC23vPS
Fever: Any ≥38 degrees C (n=263, 127)4.61.6
Fever: Mild ≥38 but <38.5 degrees C (n=263, 127)3.80.8
Fever: Moderate ≥38.5 but <39 degrees C(n=259,127)0.80.0
Fever: Severe ≥39 but ≤40 degrees C (n=259, 127)0.40.8
Fever Potentially life threatening >40C(n=258,127)0.40.0
Fatigue (n=321, 173)50.549.1
Headache (n=328, 167)49.746.1
Chills (n=286, 145)19.926.9
Rash (n=267, 134)8.613.4
Vomiting (n=261, 131)3.13.1
Decreased appetite (n=278, 148)14.723.0
New muscle pain (n=324, 167)46.951.5
Aggravated muscle pain (n=286, 154)22.032.5
New joint pain (n=278, 147)15.523.81
Aggravated joint pain (n=272, 142)14.021.1
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1)

Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.

Time frame:
14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1)
percentage of participants13vPnC13vPnC / 13vPnC
Fever: Any ≥38 degrees C (n=55, 55)9.13.6
Fever: Mild ≥38 but <38.5 degrees C (n=55, 55)7.30.0
Fever: Moderate ≥38.5 but <39 degrees C(n=55, 55)0.01.8
Fever: Severe ≥39 but ≤40 degrees C (n=55, 55)0.00.0
Fever Potentially life threatening >40C (n=55, 55)1.81.8
Fatigue (n=76, 76)56.643.4
Headache (n=76, 76)52.644.7
Chills (n=61, 61)18.019.7
Rash (n=60, 60)8.310.0
Vomiting (n=56, 56)7.13.6
Decreased appetite (n=61, 61)13.121.3
New muscle pain (n=84, 84)47.651.2
Aggravated muscle pain (n=68, 68)26.530.9
New joint pain (n=62, 62)14.516.1
Aggravated joint pain (n=62, 62)16.119.4
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1)

Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.

Time frame:
14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1)
percentage of participants13vPnC23vPS / 13vPnC
Fever: Any ≥38 degrees C (n=263, 116)4.60.9
Fever: Mild ≥38 but <38.5 degrees C (n=263, 116)3.80.9
Fever: Moderate ≥38.5 but <39 degrees C(n=259,115)0.80.0
Fever: Severe ≥39 but ≤40 degrees C(n=259,115)0.40.0
Fever Potentially life threatening >40C(n=258,115)0.40.0
Fatigue (n=321, 141)50.541.1
Headache (n=328, 139)49.740.3
Chills (n=286, 127)19.919.7
Rash (n=267, 121)8.68.3
Vomiting (n=261, 118)3.16.8
Decreased appetite (n=278, 123)14.713.0
New muscle pain (n=324, 151)46.945.0
Aggravated muscle pain (n=286, 136)22.028.7
New joint pain (n=278, 128)15.519.5
Aggravated joint pain (n=272, 131)14.021.4
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 23vPS (Year 0) and 13vPnC / 23vPS (Year 1)

Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.

Time frame:
14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 23vPS (Year 0) and 13vPnC / 23vPS (Year 1)
percentage of participants23vPS13vPnC / 23vPS
Fever: Any ≥38 degrees C (n=127, 129)1.63.1
Fever: Mild ≥38 but <38.5 degrees C (n=127, 129)0.83.1
Fever: Moderate ≥38.5 but <39 degrees C(n=127,127)0.00.0
Fever: Severe ≥39 but ≤40 degrees C(n=127,127)0.80.0
Fever Potentially life threatening >40C(n=127,127)0.00.0
Fatigue (n=173, 185)49.151.9
Headache (n=167, 175)46.149.7
Chills (n=145, 155)26.929.0
Rash (n=134, 146)13.424.0
Vomiting (n=131, 131)3.14.6
Decreased appetite (n=148, 141)23.017.0
New muscle pain (n=167, 196)51.561.2
Aggravated muscle pain (n=154, 164)32.541.5
New joint pain (n=147, 153)23.825.5
Aggravated joint pain (n=142, 143)21.117.5
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 2 (Year 1) 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC

Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.

Time frame:
14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 2 (Year 1) 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC
percentage of participants13vPnC / 13vPnC13vPnC / 23vPS23vPS / 13vPnC
Fever: Any ≥38 degrees C (n=81, 129, 116)2.53.10.9
Fever: Mild ≥38 but <38.5 degrees C (n=81,129,116)0.03.10.9
Fever: Moderate ≥38.5, <39 degrees C(n=81,127,115)1.20.00.0
Fever: Severe ≥39, ≤40 degrees C(n=81,127,115)0.00.00.0
Potentially life threatening >40C(n=81,127,115)1.20.00.0
Fatigue (n=100, 185, 141)39.051.941.1
Headache (n=96, 175, 139)41.749.740.3
Chills (n=90, 155, 127)18.929.019.7
Rash (n=86, 146, 121)10.524.08.3
Vomiting (n=82, 131, 118)3.74.66.8
Decreased appetite (n=89, 141, 123)18.017.013.0
New muscle pain (n=108, 196, 151)50.061.245.0
Aggravated muscle pain (n=94, 164, 136)26.641.528.7
New joint pain (n=87, 153, 128)14.925.519.5
Aggravated joint pain (n=91, 143, 131)17.617.521.4

Adverse events

Collected over Informed consent through 6 Month Follow-up after last vaccination. Local reactions and systemic events assessed within 14 days after vaccination 1 (Vax 1=Day 1/Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC (Year 0)—2/478 (0.4%)256/478 (53.6%)
23vPS (Year 0)—1/237 (0.4%)102/237 (43%)
13vPnC: 6 Month Follow-up After Vax 1 (Year 0)—15/478 (3.1%)41/478 (8.6%)
23vPS: 6 Month Follow-up After Vax 1 (Year 0)—6/237 (2.5%)24/237 (10.1%)
13vPnC / 13vPnC (Year 1)—0/160 (0%)97/160 (60.6%)
13vPnC / 23vPS (Year 1)—2/267 (0.7%)198/267 (74.2%)
23vPS / 13vPnC (Year 1)—1/223 (0.4%)118/223 (52.9%)
13vPnC / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1)—5/160 (3.1%)16/160 (10%)
13vPnC / 23vPS: 6 Month Follow-up After Vax 2 (Year 1)—6/267 (2.2%)23/267 (8.6%)
23vPS / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1)—3/223 (1.3%)16/223 (7.2%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
Event13vPnC (Year 0)23vPS (Year 0)13vPnC: 6 Month Follow-up After Vax 1 (Year 0)23vPS: 6 Month Follow-up After Vax 1 (Year 0)13vPnC / 13vPnC (Year 1)13vPnC / 23vPS (Year 1)23vPS / 13vPnC (Year 1)13vPnC / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1)13vPnC / 23vPS: 6 Month Follow-up After Vax 2 (Year 1)23vPS / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1)
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4780/2370/4781/2370/1601/2671/2232/1600/2670/223
Foot fractureInjury, poisoning and procedural complications0/4780/2370/4780/2370/1600/2670/2231/1600/2670/223
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4780/2371/4780/2370/1600/2670/2231/1600/2670/223
Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4780/2370/4780/2370/1600/2670/2231/1600/2670/223
Coronary artery diseaseCardiac disorders0/4780/2370/4780/2370/1600/2670/2230/1600/2671/223
Small intestinal obstructionGastrointestinal disorders0/4780/2370/4780/2370/1600/2670/2230/1601/2671/223
Non-cardiac chest painGeneral disorders0/4780/2370/4781/2370/1600/2670/2230/1601/2671/223
Accidental overdoseInjury, poisoning and procedural complications0/4780/2370/4780/2370/1600/2670/2230/1600/2671/223
Benign neoplasm of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4780/2370/4780/2370/1600/2670/2230/1600/2671/223
Angina unstableCardiac disorders0/4781/2370/4780/2370/1600/2670/2230/1600/2670/223
Most frequent other events
Showing 10 of 379
Most frequent other events
Event13vPnC (Year 0)23vPS (Year 0)13vPnC: 6 Month Follow-up After Vax 1 (Year 0)23vPS: 6 Month Follow-up After Vax 1 (Year 0)13vPnC / 13vPnC (Year 1)13vPnC / 23vPS (Year 1)23vPS / 13vPnC (Year 1)13vPnC / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1)13vPnC / 23vPS: 6 Month Follow-up After Vax 2 (Year 1)23vPS / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1)
Pain (Any)Skin and subcutaneous tissue disorders—102/175———198/231————
Pain (Any)Skin and subcutaneous tissue disorders————97/129198/231118/169———
Pain (Mild)Skin and subcutaneous tissue disorders—90/170———161/205————
Pain (Mild)Skin and subcutaneous tissue disorders————89/123161/205113/166———
Pain (Any)Skin and subcutaneous tissue disorders83/108———82/108—————
Pain (Mild)Skin and subcutaneous tissue disorders73/101———73/101—————
Pain (Any)Skin and subcutaneous tissue disorders256/370—————118/169———
Pain (Any)Skin and subcutaneous tissue disorders256/370102/175————————
Pain (Mild)Skin and subcutaneous tissue disorders238/360—————113/166———
Pain (Mild)Skin and subcutaneous tissue disorders238/36090/170————————

Baseline characteristics

Age Continuous
Age Continuous(years)13vPnC - Group 1.1 or 1.223vPS - Group 2Total
Mean61.7 ± 1.461.7 ± 1.461.7 ± 1.4
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC - Group 1.1 or 1.223vPS - Group 2Total
Female281134415
Male197103300
08

Study locations

6 sites
  • Pfizer Investigational Site
    Chandler, Arizona 85224, United States
  • Pfizer Investigational Site
    Pembroke Pines, Florida 33024, United States
  • Pfizer Investigational Site
    Boise, Idaho 83704, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina 27609, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45229, United States
  • Pfizer Investigational Site
    Bristol, Tennessee 37620, United States
09

References and documents

Publications

  • Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine. 2014 Apr 25;32(20):2364-74. doi: 10.1016/j.vaccine.2014.02.002. Epub 2014 Mar 5. PubMed 24606865 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2007
First posted
Dec 17, 2007
Start
Nov 2007
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Results first posted
May 9, 2011
Last update
Jul 22, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00574548
First posted
Dec 17, 2007
Start date
Nov 2007
Primary completion
Feb 2010
Completion
Feb 2010
Results posted
May 9, 2011
Last update
Jul 22, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion